Kolltan Pharmaceuticals Inc. To Report KTN3379 Clinical Data In An Oral Presentation At The Upcoming 2016 ASCO Annual Meeting

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for use in oncology and immunology, announced an oral presentation of clinical data for the Company’s lead product candidate, KTN3379, at the upcoming 2016 ASCO Annual Meeting, which will take place in Chicago, IL, June 3-7, 2016.